Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214436 | 0.86 | KMT2A (0.52) | PTGER1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL27632935 | 0.83 | KMT2A (0.52) | PTGER1KMT2ASTAT3 | |
| SCHEMBL7650855 | 0.82 | HTR1A (0.67) | KMT2ACARM1PRMT1KDM4EALDH1A1 | |
| SCHEMBL693828 | 0.81 | PTGER1 (0.53) | PTGER1KMT2ASTAT3 | |
| SCHEMBL1382344 | 0.80 | PTGER1 (0.54) | PTGER1KMT2AALDH1A1LMNA | |
| SCHEMBL1382347 | 0.80 | PTGER1 (0.54) | PTGER1KMT2AALDH1A1LMNA | |
| SCHEMBL4720836 | 0.79 | PTGER1 (0.56) | PTGER1STAT3 | |
| SCHEMBL562155 | 0.78 | PTGER1 (0.55) | PTGER1STAT3 | |
| SCHEMBL2954443 | 0.78 | MAPT (0.60) | PTGER1 | |
| SCHEMBL1196687 | 0.78 | CCR5 (0.64) | PTGER1KMT2ASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1832928-B | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2012-07-04 | — | — | CN | claimed |
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| CN-1832928-A | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | claimed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | PTGER1 702/4885KMT2A 3472/4885CARM1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.